Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 11/20 | 0.39 |
| ▸ | NPC1 | O15118 | 10/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3890738 | 0.78 | KMT2A (0.57) | KMT2ATHRBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2231665 | 0.77 | KMT2A (0.52) | KMT2ATHRBRAB9ANPC1SMN1; SMN2 | |
| Bromide SCHEMBL1647384 | 0.75 | KMT2A (0.55) | KMT2ATHRBRAB9ANPC1SMN1; SMN2 | |
| Bromide SCHEMBL3897209 | 0.73 | KMT2A (0.63) | KMT2ATHRBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13394254 | 0.72 | KMT2A (0.70) | KMT2ATHRBRAB9ANPC1SMN1; SMN2 | |
| Bromide SCHEMBL1647594 | 0.72 | KMT2A (0.51) | KMT2ANAPRTTHRBRAB9ANPC1 | |
| SCHEMBL3403133 | 0.72 | NAPRT (0.60) | KMT2ANAPRTTHRBRAB9ANPC1 | |
| Bromide SCHEMBL1645919 | 0.71 | KMT2A (0.73) | KMT2ATHRBRAB9ANPC1SMN1; SMN2 | |
| Bromide SCHEMBL3890163 | 0.70 | KMT2A (0.49) | KMT2ATHRBRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL8120684 | 0.70 | KMT2A (0.54) | KMT2ATHRBRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LTD (GB) | 2011-07-28 | — | — | US | disclosed |
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD. | 2010-03-04 | — | — | US | disclosed |
| WO-2009144473-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LIMITED (GB) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | IDO1, FOXM1, IPO5 | KMT2A 3693/4885NAPRT 2001/4885THRB 3738/4885 |
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | NAT1, AGXT, CYP1A2 | KMT2A 1472/4885NAPRT 1235/4885THRB 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.